Journal of Clinical Oncology
Articles in this Issue
Morphologic and genomic changes in clinical relapse of young onset tongue cancer.
e18133 Background: The morphological and genomic changes associated with relapse in young-onset tongue cancer remain uncle...
Efficacy and safety analysis of furmonertinib in the treatment of <i>EGFR</i> -mutated lung adenocarcinoma: A single-center real-world study based on high-risk stratification.
8651 Background: Real-world data on furmonertinib, a third-generation EGFR-TKI, for high-risk EGFR-mutant NSCLC patients (...
Benchmarking survival outcomes of quemliclustat in first-line metastatic pancreatic ductal adenocarcinoma: Insights from ARC-8 and implications for PRISM-1.
e16396 Background: Outcomes in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) remain poor, with gemcitabin...
Promoting acral melanoma awareness among nail salon technicians and cosmetology educators in California: A theoretically grounded qualitative needs assessment.
e22567 Background: A growing body of literature has explored the role of cosmetology professionals in promoting early comm...
Intelligence-driven data extraction for the breast cancer multidisciplinary team meeting case preparation: Results from a prospective external validation.
e13669 Background: Cancer Multi-Disciplinary Team Meetings (MDTMs) are central to UK Cancer Pathways irrespective of patie...
Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.
599 Background: Standard neoadjuvant regimens for HER2-positive early breast cancer (EBC), such as 6 cycles of TCHP, achie...
Association between breast cancer located in the upper outer quadrant (UOQ) and axillary lymph node metastasis (N1 disease): Clinical implications and prognostic significance.
e12764 Background: While tumor location influences lymphatic drainage patterns, its prognostic value in node-positive dise...
MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM).
TPS7579 Background: Cemsidomide is a novel, highly potent, cereblon-based, IKZF1/3 MonoDAC degrader, having a similar mech...
A phase II clinical study of stereotactic radiotherapy (SRT) combined with chemotherapy and tislelizumab for the treatment of metastatic nasopharyngeal carcinoma.
e18020 Background: In general, immune checkpoint inhibitors combined with chemotherapy can benefit patients with metastati...
Historical redlining and oral squamous cell carcinoma staging at diagnosis.
e22598 Background: Previous research has shown that residents in historically redlined zones, areas defined from the discr...
Impact of disseminated intravascular coagulation on in-hospital outcomes in patients with multiple myeloma: A nationwide analysis.
e19557 Background: Disseminated intravascular coagulation (DIC) is an uncommon but severe hematologic complication in mult...
Association of PCSK9 inhibitors with clinical outcomes in patients with cancer receiving immune checkpoint inhibitors: A real-world analysis.
2657 Background: Although developed as lipid-lowering agents, PCSK9 inhibitors (PCSK9i) have shown preclinical potential t...
An automated, EHR-integrated intervention system for patient-reported insomnia symptoms.
12058 Background: Insomnia affects >20% of patients on cancer therapy. It is consistently reported to be one of the mos...
NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
TPS9610 Background: Neoadjuvant immunotherapy (NAT) with immune checkpoint inhibitors (ICI) has emerged as superior treatm...
A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer.
2576 Background: The treatment paradigm for advanced/recurrent endometrial cancer (EC) is undergoing rapid transformation....
Risk of non-Hodgkin lymphoma in sarcoidosis patients with salivary gland involvement: A retrospective cohort study.
e19060 Background: Sarcoidosis is an inflammatory disease characterized by non-caseating granulomas that most commonly aff...
Liver transplantation (LT) in liver limited metastatic colorectal cancer (CRC): Insights and opportunities.
3608 Background: Liver transplantation (LT) for liver limited metastatic colorectal cancer (LL-mCRC) remains underutilized...
Evaluating the impact of the 2021 USPSTF age expansion (50–54 years) on racial disparities in early-stage lung cancer diagnosis.
10546 Background: In 2021, the USPSTF updated its guidelines to address known racial disparities in lung cancer outcomes....
The inpatient cancer diagnostic service: An academic cancer center experience.
e23015 Background: Rapid inpatient cancer diagnosis may reduce time to treatment and improve outcomes, particularly among...
Trends in locoregional colorectal cancer incidence by socioeconomic factors in US adults aged 45-49 with updated screening guidelines (2013-2022).
e15686 Background: Colorectal cancer (CRC) screening guidelines from the American Cancer Society recommended lowering the...
Risk stratification for prostate cancer screening using PSA and prostate volume.
e17000 Background: Prostate-specific antigen (PSA) testing is widely used for prostate cancer screening but is lim...
A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.
TPS4641 Background: Patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) who progress after an...
The neurotoxicity rating scale: A novel patient-reported outcome (PRO) measure for neuro-psycho-behavioral late effects in head and neck cancer (HNC) survivors.
12115 Background: Chronic fatigue, mood disorders and cognitive dysfunction are well recognized but understudied late toxi...
Impact of GLP1 receptor agonists on survival of breast cancer patients.
639 Background: Large cohort studies have shown a survival benefit with the use of GLP1 receptor agonists (GLP1 RA) in can...
Evaluation of imiquimod treatment outcomes in vulvar melanoma.
5540 Background: Vulvar and vaginal melanomas account for approximately 10% of vulvar malignancies and less than 1% of all...